Virginia Catani

Dr. Virginia Catani

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 June 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
ASAnna Valeria Samarelli
Anna Valeria Samarelli
Roberto TonelliRoberto Tonelli
Roberto Tonelli
GRGiulia Raineri
Giulia Raineri
IMilenia mastrolia
ilenia mastrolia
MCMatteo Costantini
Matteo Costantini
Enrico M. CliniEnrico M. Clini
Enrico M. Clini
Background: The molecular pathways involved in the onset and progression of idiopathic pulmonary fibrosis (IPF) still need to be fully clarified as some are shared with lung cancer development. HOXB7, a member of the homeobox (Hox) gene family, has been found involved in various cancers. Methods: Immunohistochemical (IHC) analysis was run on lung tissue samples from surgical lung biopsy (SLB) of 19 patients with IPF, retrospectively selected from the IPF database of the University Hospital of Modena. HOXB7 expression was analyzed and compared with that of five patients with no evidence of pulmonary fibrosis as controls. Results: The semi-quantitative analysis of IHC showed that HOXB7 protein expression was higher in IPF patients compared to controls (difference between means = 6.2 ± 2.37, p = 0.0157). Further, HOXB7 expression was higher in IPF patients with a higher extent of fibrosis (50–75%)—measured with high-resolution computer tomography—compared to those with a lower extent (0–25%) (difference between means = 25.74 ± 6.72, p = 0.004). Conclusions: The expression of HOXB7 is higher in the lung of IPF patients compared to controls, and was represented in different cellular compartments within the lung niche. Further investigations are needed to clarify its role in the pathogenesis and progression of IPF.

17 June 2023 in Biology
Verified
Journal Article
Open access
PDF file
IMilenia mastrolia
ilenia mastrolia
Virginia CataniVirginia Catani
Virginia Catani
MOMarco Oltrecolli
Marco Oltrecolli
SPStefania Pipitone
Stefania Pipitone
MVMaria Giuseppa Vitale
Maria Giuseppa Vitale
MDMassimo Dominici
Massimo Dominici
Renal cell carcinoma (RCC) is the second most common cancer of the urinary system. The current therapeutic strategies are based on partial or total nephrectomy and/or targeted therapies based on immune checkpoint inhibitors to which patients are often refractory. Preventive and screening strategies do not exist and the few available biomarkers for RCC are characterized by a lack of sensitivity, outlining the need for novel noninvasive and sensitive biomarkers for early diagnosis and better disease monitoring. Blood liquid biopsy (LB) is a non- or minimally invasive procedure for a more representative view of tumor heterogeneity than a tissue biopsy, potentially allowing the real-time monitoring of cancer evolution. Growing interest is focused on the extracellular vesicles (EVs) secreted by either healthy or tumoral cells and recovered in a variety of biological matrices, blood included. EVs are involved in cell-to-cell crosstalk transferring their mRNAs, microRNAs (miRNAs), and protein content. In particular, transferred miRNAs may regulate tumorigenesis and proliferation also impacting resistance to apoptosis, thus representing potential useful biomarkers. Here, we present the latest efforts in the identification of circulating miRNAs in blood samples, focusing on the potential use of EV-derived miRNAs as RCC diagnostic and prognostic markers.

28 April 2023 in Preprints.org
Verified
Preprint
Open access
PDF file
IMilenia mastrolia
ilenia mastrolia
Virginia CataniVirginia Catani
Virginia Catani
MOMarco Oltrecolli
Marco Oltrecolli
SPStefania Pipitone
Stefania Pipitone
MVMaria Giuseppa Vitale
Maria Giuseppa Vitale
MDMassimo Dominici
Massimo Dominici
Renal cell carcinoma (RCC) is the second most common cancer of the urinary system. The current therapeutic strategies are based on partial or total nephrectomy and/or targeted therapies based on immune checkpoint inhibitors to which patients are often refractory. Preventive and screening strategies are not existing and the few available biomarkers for RCC are characterized by the lack of sensitivity, outlining the need of novel noninvasive and sensitive biomarkers for an early diag-nosis and a better disease monitoring. Blood liquid biopsy (LB) is a non- or minimally invasive procedure for a more representative view of tumor heterogeneity than the tissue biopsy, poten-tially allowing real-time monitoring of cancer evolution. Growing interest is focused on the extra-cellular vesicles (EVs) secreted by either healthy or tumoral cells and recovered in a variety of bio-logical matrices, blood included. EVs are involved in cell-to-cell crosstalk transferring their mRNAs, miRNAs, and proteins content. In particular, transferred miRNAs may regulate the tu-morigenesis and proliferation also impacting on resistance to apoptosis, thus representing poten-tial useful biomarkers. Here we present the latest efforts in the identification of circulating miR-NAs in blood samples, focusing on the potential use of EV derived miRNAs as RCC diagnostic, prognostic markers.

30 May 2026 in Cytopathology
Verified
Journal Article
Open access
Rita LeporatiRita Leporati
Rita Leporati
VCV. Callegari
V. Callegari
AAA. Ancora
A. Ancora
MPM. Palmieri
M. Palmieri
BRB. Riccò
B. Riccò
FBF. Bertolini
F. Bertolini
Immune checkpoint inhibitors (ICIs) have revolutionised the treatment landscape of non‐small cell lung cancer (NSCLC) without actionable genomic alterations by opening new possibilities for treatment. However, the predictive value of Programmed Death‐Ligand 1 (PD‐L1) expression assessed by immunohistochemistry (IHC) is quite modest, leaving many patients without optimal benefit from ICIs. To address this gap, liquid biopsy is gaining momentum as a promising tool to complement tissue‐based PD‐L1 assessment. Liquid biopsy, which entails the analysis of circulating tumour cells (CTCs), extracellular vesicles (EVs), circulating tumour DNA (ctDNA), and other biomarkers, offers a non‐invasive approach for tracking disease evolution and interactions with the immune system. We conducted a narrative review to explore the potential of liquid biopsy in enhancing patient selection for ICIs, its predictive and prognostic value in advanced NSCLC, and the associated technical and clinical implications. By highlighting recent advancements and ongoing research efforts, we underscore the critical role of liquid biopsy in driving precision immuno‐oncology. Establishing robust, reproducible methods for PD‐L1 assessment through liquid biopsy is essential for translating this approach into clinical practice, with the potential to overcome the limitations of tissue‐based assays and better individualise immunotherapy strategies in NSCLC.

20 February 2025 in Cancer Medicine
Verified
Journal Article
Open access
CPClaudia Piombino
Claudia Piombino
CNCecilia Nasso
Cecilia Nasso
SBStefania Bettelli
Stefania Bettelli
SMSamantha Manfredini
Samantha Manfredini
MVMaria Giuseppa Vitale
Maria Giuseppa Vitale
RSRoberto Sabbatini
Roberto Sabbatini
Background: The therapeutic management of metastatic hormone‐sensitive prostate cancer (mHSPC) is still based on clinical and pathological parameters due to the lack of biomarkers that may drive tailored treatment.Methods: In this non‐randomized, single‐center, retrospective trial, we searched for a genetic signature using the NanoString nCounter PanCancer Pathways Panel on formalin‐fixed paraffin embedded prostate cancer samples belonging to 48 patients with de novo or relapsed mHSPC. Patients were divided into a high‐clinical‐risk group (n = 36) and a low‐clinical‐risk group (n = 12) according to the mean time to metastatic relapse.Results: The analysis of Nanostring nCounter Panel data revealed differential expression of 42 genes between high‐clinical‐risk and low‐clinical‐risk groups. All the genes except for NR4A1 and FOS were upregulated in the high‐clinical‐risk group. A general overexpression of apoptosis, PI3K and MAPK pathway‐related genes, including AKT2, was observed in the high‐clinical‐risk group.Conclusion: The differential genetic signature identified between the two study groups revealed novel biomarkers in mHSPC, additionally suggesting new therapeutic targets within the hormone sensitive phase, such as AKT2. Further prospective larger cohort studies are needed to assess the prognostic value of our findings and their exact role in prostate cancer progression.